WS Investor
04 Nov 2025, 15:12
Nuvectis Pharma Advances NXP900 Clinical Program; Reports Q3 2025 Results
Nuvectis Pharma, Inc. (NASDAQ: NVCT) reported third-quarter 2025 financial results and provided updates on the clinical progress of its lead candidate, NXP900. The company has initiated its Phase 1b single-agent study, targeting patients with advanced cancers defined by specific molecular and histological profiles, and plans to launch the combination therapy phase by the end of 2025.
The Phase 1a dose escalation and drug-drug interaction studies were successfully completed, demonstrating robust pharmacodynamic responses and supporting once-daily oral dosing and combination potential. Data presented at the AACR-NCI-EORTC 2025 conference further reinforced NXP900’s biomarker-based patient selection approach.
CEO Ron Bentsur emphasized that the company’s focus is now on advancing NXP900 through Phase 1b, exploring its potential to overcome resistance when combined with established cancer therapies.
Financially, Nuvectis reported a net loss of $7.5 million for Q3 2025, compared with $4.2 million a year earlier, mainly due to a $2 million milestone payment and $0.7 million in drug interaction study costs. Research and development expenses rose to $5.8 million from $2.8 million, while general and administrative costs increased to $2 million from $1.5 million.
Cash and equivalents stood at $35.4 million as of September 30, 2025, up from $18.5 million at year-end 2024, primarily driven by a February public offering and ATM facility proceeds. The company projects its cash runway will sustain operations into the third quarter of 2027.
Nuvectis Pharma, Inc. (NASDAQ: NVCT) reported third-quarter 2025 financial results and provided updates on the clinical progress of its lead candidate, NXP900. The company has initiated its Phase 1b single-agent study, targeting patients with advanced cancers defined by specific molecular and histological profiles, and plans to launch the combination therapy phase by the end of 2025.
The Phase 1a dose escalation and drug-drug interaction studies were successfully completed, demonstrating robust pharmacodynamic responses and supporting once-daily oral dosing and combination potential. Data presented at the AACR-NCI-EORTC 2025 conference further reinforced NXP900’s biomarker-based patient selection approach.
CEO Ron Bentsur emphasized that the company’s focus is now on advancing NXP900 through Phase 1b, exploring its potential to overcome resistance when combined with established cancer therapies.
Financially, Nuvectis reported a net loss of $7.5 million for Q3 2025, compared with $4.2 million a year earlier, mainly due to a $2 million milestone payment and $0.7 million in drug interaction study costs. Research and development expenses rose to $5.8 million from $2.8 million, while general and administrative costs increased to $2 million from $1.5 million.
Cash and equivalents stood at $35.4 million as of September 30, 2025, up from $18.5 million at year-end 2024, primarily driven by a February public offering and ATM facility proceeds. The company projects its cash runway will sustain operations into the third quarter of 2027.